Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1161/JAHA.116.003350 http://scihub22266oqcxt.onion/10.1161/JAHA.116.003350 C4859299!4859299!27098970     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Am+Heart+Assoc 2016 ; 5 (4): ä Nephropedia Template TP {{tp|p=27098970|t=2016. Comparative Effectiveness of Generic Atorvastatin and Lipitor® in Patients Hospitalized with an Acute Coronary Syndrome |pdf=|usr=}}{{27098970}} gab.com Text Comparative Effectiveness of Generic Atorvastatin and Lipitor® in Patients Hospitalized with an Acute Coronary Syndrome JO: J Am Heart Assoc http://www.kidney.de/pget.php?&tw=1&pmid=27098970 #FOAvip Background: Although generic medications are approved based on bioequivalence with brand?name medications, there remains substantial concern regarding their clinical effectiveness and safety. Lipitor®, available as generic atorvastatin, is one of the most commonly prescribed statins. Therefore, we compared the effectiveness of generic atorvastatin products and Lipitor®. Methods and Results: We conducted a population?based cohort study, using propensity score matching to minimize potential confounding of patients ?65 years, discharged alive after acute coronary syndrome (ACS) hospitalization between 2008 and 2012 in Ontario, Canada, who were prescribed Lipitor® or generic atorvastatin within 7 days of discharge. The primary outcome was 1?year death/recurrent ACS hospitalization. Secondary outcomes included hospitalization for heart failure, stroke, new?onset diabetes, rhabdomyolysis, and renal failure. In the 7863 propensity?matched pairs (15 726 patients), mean age was 76.9 years, 56.3% were male, 87.6% had myocardial infarction, and all patients had complete follow?up. At 1 year, 17.7% of those prescribed generic atorvastatin and 17.7% of those prescribed Lipitor® experienced death or recurrent ACS (hazard ratio, 1.00; 95% CI, 0.93?1.08; P=0.94). No significant differences in rates of secondary outcomes between groups were observed. Prespecified subgroup analyses by age, sex, diabetes, atorvastatin dose, or admission diagnosis found no outcome difference between groups. Conclusions: Among older adults discharged alive after ACS hospitalization, we found no significant difference in cardiovascular outcomes or serious, infrequent side effects in patients prescribed generic atorvastatin compared with those prescribed Lipitor® at 1 year. Our findings support the use of generic atorvastatin in ACS, which could lead to substantial cost saving for patients and health care plans without diminishing population clinical effectiveness. Twit Text FOAVip Comparative Effectiveness of Generic Atorvastatin and Lipitor® in Patients Hospitalized with an Acute Coronary Syndrome ????J Am Heart Assoc http://www.kidney.de/pget.php?&tw=1&pmid=27098970 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27098970 #FOAvip English Wikipedia <ref>{{Cite pmid|27098970}}</ref> Comparative Effectiveness of Generic Atorvastatin and Lipitor® in Patients Hospitalized with an Acute Coronary Syndrome #MMPMID27098970 Jackevicius CA; Tu JV; Krumholz HM; Austin PC; Ross JS; Stukel TA; Koh M; Chong A; Ko DT J Am Heart Assoc 2016[Apr]; 5 (4): ä PMID27098970show ga Background: Although generic medications are approved based on bioequivalence with brand?name medications, there remains substantial concern regarding their clinical effectiveness and safety. Lipitor®, available as generic atorvastatin, is one of the most commonly prescribed statins. Therefore, we compared the effectiveness of generic atorvastatin products and Lipitor®. Methods and Results: We conducted a population?based cohort study, using propensity score matching to minimize potential confounding of patients ?65 years, discharged alive after acute coronary syndrome (ACS) hospitalization between 2008 and 2012 in Ontario, Canada, who were prescribed Lipitor® or generic atorvastatin within 7 days of discharge. The primary outcome was 1?year death/recurrent ACS hospitalization. Secondary outcomes included hospitalization for heart failure, stroke, new?onset diabetes, rhabdomyolysis, and renal failure. In the 7863 propensity?matched pairs (15 726 patients), mean age was 76.9 years, 56.3% were male, 87.6% had myocardial infarction, and all patients had complete follow?up. At 1 year, 17.7% of those prescribed generic atorvastatin and 17.7% of those prescribed Lipitor® experienced death or recurrent ACS (hazard ratio, 1.00; 95% CI, 0.93?1.08; P=0.94). No significant differences in rates of secondary outcomes between groups were observed. Prespecified subgroup analyses by age, sex, diabetes, atorvastatin dose, or admission diagnosis found no outcome difference between groups. Conclusions: Among older adults discharged alive after ACS hospitalization, we found no significant difference in cardiovascular outcomes or serious, infrequent side effects in patients prescribed generic atorvastatin compared with those prescribed Lipitor® at 1 year. Our findings support the use of generic atorvastatin in ACS, which could lead to substantial cost saving for patients and health care plans without diminishing population clinical effectiveness. äComparative Effectiveness of Generic Atorvastatin and Lipitor® in Pati(epmc).pdf DeepDyve Pubget Overpricing